Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker ADAPY
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G | ADAPY Adaptimmune Therapeutics PLC | John Helmers | 0 | 0.0% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | ADAPY Adaptimmune Therapeutics PLC | Long Focus Capital Management, LLC | 0 | 0.0% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Sina Toussi | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Two Seas Capital GP LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Two Seas Capital LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Scott D. Sandell | 4 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Mohamad H. Makhzoumi | 4 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Patrick J. Kerins | 4 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Anthony A. Florence, Jr. | 4 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Forest Baskett | 4 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Nea 16 GP, LLC | 4 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ADAPY Adaptimmune Therapeutics PLC | NEA Partners 16, L.P. | 4 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ADAPY Adaptimmune Therapeutics PLC | New Enterprise Associates 16, L.P. | 4 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Nea 14 GP, Ltd | 4 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ADAPY Adaptimmune Therapeutics PLC | NEA Partners 14, L.P. | 4 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ADAPY Adaptimmune Therapeutics PLC | New Enterprise Associates 14, L.P. | 4 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | EcoR1 Capital Fund Qualified, L.P. | 63.18M | 4.0% | SCHEDULE 13G/A ↗ |
| Aug 19, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Oleg Nodelman | 66.00M | 4.2% | SCHEDULE 13G/A ↗ |
| Aug 19, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | EcoR1 Capital, LLC | 66.00M | 4.2% | SCHEDULE 13G/A ↗ |
| Aug 13, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Sina Toussi | 135.48M | 8.5% | SCHEDULE 13G/A ↗ |
| Aug 13, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Two Seas Capital GP LLC | 135.48M | 8.5% | SCHEDULE 13G/A ↗ |
| Aug 13, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Two Seas Capital LP | 135.48M | 8.5% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Sina Toussi | 123.18M | 8.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Two Seas Capital GP LLC | 123.18M | 8.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Two Seas Capital LP | 123.18M | 8.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G | ADAPY Adaptimmune Therapeutics PLC | Sina Toussi | 89.01M | 5.8% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | ADAPY Adaptimmune Therapeutics PLC | Two Seas Capital GP LLC | 89.01M | 5.8% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | ADAPY Adaptimmune Therapeutics PLC | Two Seas Capital LP | 89.01M | 5.8% | SCHEDULE 13G ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Baillie Gifford & Co | 70.91M | 4.6% | SCHEDULE 13G/A ↗ |
| Feb 11, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Glenn Helmers | 7.14M | 2.8% | SCHEDULE 13G/A ↗ |
| Feb 11, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | John Helmers | 20.49M | 8.0% | SCHEDULE 13G/A ↗ |
| Feb 11, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Condagua, LLC | 7.14M | 2.8% | SCHEDULE 13G/A ↗ |
| Feb 11, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Long Focus Capital Master, Ltd. | 13.35M | 5.2% | SCHEDULE 13G/A ↗ |
| Feb 11, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Long Focus Capital Management, LLC | 20.49M | 8.0% | SCHEDULE 13G/A ↗ |
| Jan 8, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | David E. Goel | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Jan 8, 2025 | SCHEDULE 13G/A (amended) | ADAPY Adaptimmune Therapeutics PLC | Matrix Capital Management Company LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
36 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:52 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances